Johnson & Johnson Weighs DePuy Synthes Exit Amid Portfolio Reset

Johnson & Johnson (JNJ) is reportedly in talks to sell its DePuy Synthes orthopedics unit to Apollo Global Management. The potential transaction would involve J&J's orthopedics franchise within its MedTech segment, including DePuy Synthes assets.

A sale of DePuy Synthes to Apollo would represent a significant reshaping of Johnson & Johnson's medical devices portfolio. This move is part of a broader repositioning of the company that our analysis has highlighted.

Johnson & Johnson is a US healthcare group with a reported market value of about $641.9 billion, spanning pharmaceuticals, medical devices, and consumer health products worldwide.